7AL0.F Alligator Bioscience AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.0001 EUR
Close of Oct 29, 2026
0.0001 0.0889
Market cap
EUR 357K
P/E
-
P/B
0.17x
ROE
-305.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 7AL0.F undervalued?

Graham number

The Graham number of Alligator Bioscience AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Alligator Bioscience AB (publ) fundamental analysis

No fundamental analysis for Alligator Bioscience AB (publ) yet.

Alligator Bioscience AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Alligator Bioscience AB (publ)

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage …

Full company profile